Funding For 'Holy Grail' Of Anticoagulant Drugs, University Of Cambridge
XO1 Ltd, a University of Cambridge and Addenbrooke's Hospital spin-out company, has raised $11 million in funding to develop a new anticoagulant medication which prevents stroke and heart attacks without causing bleeding. The company explained that the new drug, a synthetic antibody called Ichorcumab, has the potential to save millions of lives. Funding for the Ichorcumab research came from Index Ventures, a life science investor...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Blood / Hematology Source Type: news
More News: Bleeding | Cardiology | Funding | Health | Heart | Hematology | Hospitals | Science | Stroke